Drug Profile

CTX 120

Alternative Names: CTX-120

Latest Information Update: 28 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CRISPR Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma
New Molecular Entity No

Highest Development Phases

No development reported Multiple myeloma

Most Recent Events

28 Feb 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in USA (IV, Infusion)
28 Oct 2020 CTX 120 receives Orphan Drug status for Multiple myeloma (Second-line therapy or greater) in USA
22 Jan 2020 Phase-I clinical trials in Multiple myeloma (Second line therapy or greater) in USA (IV) (NCT04244656)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com